Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 2, p. s1, 2022. DOI: 10.25251/skin.6.supp.1. Disponível em: https://skin.dermsquared.com/skin/article/view/1516. Acesso em: 18 may. 2025.